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A B S T R A C TObjectives: Major depressive disorder (MDD) is a chronic illness
associated with a major burden on quality of life (QOL) and health
care resources. Aripiprazole augmentation to antidepressant treat-
ment was recently approved for patients with MDD responding
insufﬁciently to antidepressant treatment in Turkey. The objective
was to estimate the cost-effectiveness of aripiprazole augmentation
in this indication compared with olanzapine and quetiapine augmen-
tation from a payer perspective. Methods: A lifetime economic model
was built simulating transitions of patients with MDD between major
depressive episodes (MDEs) and remission. During MDEs, patients
were treated with adjunctive aripiprazole, quetiapine, or olanzapine.
Patients who did not respond switched to subsequent treatment lines.
Comparative effectiveness between adjunctive aripiprazole, quetia-
pine, and olanzapine was estimated by using an indirect comparison.
Resource utilization and costs were obtained from Turkish studies.
Results: Over a lifetime horizon, patients treated with aripiprazole
spent less time in MDEs than did patients treated with quetiapine (−11
weeks) and olanzapine (−7 weeks). On average, patients treated withsee front matter Copyright & 2013, International S
r Inc.
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ndence to: Mete Saylan, Market Access Departmenaripiprazole showed improvement in QOL compared with patients
treated with quetiapine (þ0.054 quality-adjusted life-years [QALYs])
and olanzapine (þ0.039 QALYs) combined with cost saving of 593
Turkish lira (TL) versus quetiapine and 485 TL versus olanzapine. The
probability that adjunctive aripiprazole would be cost-effective among
the three strategies ranged between 74% and 75% for willingness-to-
pay values between 0 TL and 100,000 TL per QALY gained. Conclu-
sions: This is the ﬁrst lifetime health-economic model in Turkey that
takes patient heterogeneity into account when assessing QOL and
costs of different adjunctive strategies in MDD. The results indicate
that adjunctive treatment with aripiprazole provides health beneﬁts
at lower costs in patients with MDD when compared with quetiapine
and olanzapine augmentation.
Keywords: antipsychotics, aripiprazole, cost-effectiveness analysis,
depression, discrete probability distribution, major depressive
disorder, olanzapine, quetiapine, simulation model, Turkey.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Mood disorders represent a major health problem. Depression is a
frequent and severe illness with a substantial impact on personal
and familial suffering. Several surveys such as the National
Comorbidity Survey Replication in the United States have shown
a lifetime prevalence of mood disorders of more than 20% in
adults [1]. Most of this prevalence was associated with major
depression, which had a lifetime prevalence of 16.6%. In theWorld
Health Organization’s World Mental Health Survey Initiative, the
projected lifetime prevalence of any mood disorder was 31.4% in
the United States [2]. In the European Study of the Epidemiology of
Mental Disorders, 13% of the individuals reported a history of
major depression, with a 12-month prevalence of 4% [3]. In
Turkey, the prevalence of depression was estimated to be 21% in
2004 [4]. Depression is a highly recurrent disease; 80% of thepatients with a history of two episodes will have another recur-
rence during their lifetime [5]. Because of the high risk of suicide
(6.3% annually [6]), depression can be a life-threatening illness.
According to the World Health Organization, major depression
is currently ranked as the leading cause of disability in middle-
and high-income countries. At an international level, 4.1% of the
total global burden of disease is due to major depression [7].
Depression, being an important source of impaired health-related
quality of life (HRQOL) of patients [8,9], was also the fourth
leading cause of disease burden in Turkey [4]. Depression pri-
marily impacts the usual activities, pain and discomfort, and
anxiety and depression domains on the EuroQol ﬁve-dimensional
questionnaire [10]. Reported utility values for depressive episodes
were between 0.09 and 0.47 [10–14]. Total cost for depression was
estimated at $267 million in Turkey in 2004, primarily related to
hospital-based treatment (93%) [15].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
o conﬂicts of interest with regard to the content of this article.
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is remission, that is, a full symptomatic recovery with a return to
premorbid functioning. Indeed, partial remission is associated
with a greater risk of relapse and recurrence, decreased quality of
life, a poorer psychosocial functioning, a higher mortality risk,
and increased cost of illness. A Swedish study has shown that
patients who are not in remission use 1.6 times more medical
resources than do those in remission [16].
In the Sequenced Treatment Alternatives to Relieve Depres-
sion (STAR*D) study, less than 30% of the patients reached
remission with ﬁrst-step antidepressant treatment within 14
weeks of starting treatment [17,18]. Another recent study per-
formed in primary care also reported very low remission rates
with antidepressant treatment: 28.3% according to the clinicians
and 17.1% according to the patients [19]. For these insufﬁcient
responders to antidepressant treatment, one may consider
increasing the dose or switching to another antidepressant,
depending on the level of initial response. Alternatively, the
treatment of patients with an insufﬁcient response to an anti-
depressant may be augmented with an atypical antipsychotic.
Turkey was the ﬁrst country in Europe to approve aripiprazole
augmentation for the treatment of major depressive episodes in
patients who showed inadequate response after at least one
antidepressant treatment [20]. For reimbursement decisions, it is
important to consider the value for money of this strategy
compared with other alternatives. Quetiapine augmentation is
also approved for this indication in Turkey [20], and olanzapine
augmentation is used off-label (it is not ofﬁcially approved in
Turkey but has a US license as combination with ﬂuoxetine
[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/0205
92s060s061,021086s038s039lbl.pdf]). The short-term use of these
regimens has been compared in a recent cost-effectiveness
analysis in the United States [21]. A Turkish cost-effectiveness
assessment, however, is still missing. As such, this article aimed
to assess the cost-effectiveness of aripiprazole augmentation
compared with that of quetiapine and olanzapine augmentation
for the treatment of major depressive disorder (MDD) in Turkey
from a payer perspective.Methods
Model Structure
A patient-level simulation model was built structuring the evi-
dence on clinical and economic outcomes of treating patients
suffering from MDD with adjunctive aripiprazole compared with
adjunctive quetiapine and adjunctive olanzapine. The model was
built in Microsoft Excel and Visual Basic for applications. A total
of 50,000 patients were simulated to reach stable results.
A microsimulation approach was deemed most appropriate in
this indication, due to the heterogeneity of the patient population
and the strong association between a patient’s history and his or
her future disease course. To represent this with a Markov model
would require too many health states. A schematic overview of
the simulation model structure is presented in Figure 1, repre-
senting the modeled health states and possible transitions. The
depressive episode is the initial health state of a patient. Duration
was simulated to determine the time at which a patient wouldTable 1 – Baseline patient characteristics [13–15] and cor
Characteristic Mean  SD
Age (y) 45.1  4.4
Gender (% males) 68.0
Number of prior episodes 6  5.2move to the remission state. Once there, the time until a next
depressive episode was simulated, specifying the length of stay
in remission. If that period was longer than 9 months, a patient
spent the remaining time in the “between episodes” state,
incurred fewer costs and experienced further quality of life
improvements. Back in the depressive episode state, the proce-
dure was repeated until a patient died. Time of death was
simulated at model entrance (based on age and gender) and
could be shortened if a patient committed suicide, which was
possible only during a depressive episode. During each depres-
sive episode it was simulated whether a patient had committed
suicide. It was assumed that this would take place in the middle
of the episode. Further model details are provided in the follow-
ing sections.
Patient Population Simulated
The characteristics of the patients that were simulated at model
entrance resemble the populations enrolled in the double-blind
randomization phases of the three clinical trials assessing the
efﬁcacy of aripiprazole augmentation [22–24]. The patients in
these trials suffered from a major depressive episode and had an
insufﬁcient response to at least two prior antidepressant thera-
pies prior to trial entry. Their characteristics and the distributions
used for simulating them in the model are provided in Table 1.
Clinical Data
The time a patient spent in the depressive episode state
depended on the remission rate of the therapy. Remission rates
with aripiprazole augmentation were based on the three clinical
trials assessing the efﬁcacy of aripiprazole as adjunctive therapy
in MDD [22–24]. During a 6-week treatment period, 28.8% of the
patients reached remission (see Table 2). A Bernoulli distribution
with a probability of 0.288 was used in the model to simulate
whether a patient would respond to aripiprazole augmentation
within 6 weeks. This discrete probability distribution takes a
value of 1 (response) with a probability of 28.8% and a value of
0 (no response) with a probability of 71.2%. A remitting patient
would move to the remission state after 6 weeks. Patients not
reaching remission after 6 weeks remained in the depressive
state and were switched to a subsequent treatment line (see
Fig. 2). Comparative 6-week remission rates of the other adjunc-
tive strategies were based on a formal indirect comparison due to
a lack of direct comparable data in this indication. To estimate
the efﬁcacy of other adjunctive strategies, a systematic review
was conducted identifying head-to-head or placebo controlled
studies (PCSs) of antidepressant augmentation with aripiprazole,responding distributions used for simulating.
Distribution Parameter (s)
Normal m ¼ 45.1, s ¼ 4.4
Bernoulli P ¼ 0.68
Geometric P ¼ 0.17
Table 2 – Health economic model input parameters.
Remission probability (%) at 6 wk
Aripiprazole augmentation 28.8 (25.0–33.0)
Quetiapine augmentation 24.5 (16.7–32.2)
Olanzapine ﬂuoxetine combination 25.4 (18.2–33.2)
Lithium augmentation 16.0 (1.00–44.6)
Triiodothyronine augmentation 67.9 (14.5–89.8)
Best supportive care (yearly hazard) 0.78
Remission probability prior responders 90.0 (50.0–99.0)
Depressive episode Remission Between episodes
Utility values 0.46 (0.34–0.58) 0.81 (0.76– 0.86) 0.86 (0.84–0.88)
Costs ($/TL)
Aripiprazole augmentation 221 (108–327) 119 (48–186) 4
Quetiapine augmentation 200 (87–306) 119 (48–186) 4
Olanzapine ﬂuoxetine combination 210 (96, 316) 119 (48–186) 4
Lithium augmentation 188 (74–294) 119 (48–186) 4
Triiodothyronine augmentation 187 (74–293) 119 (48–186) 4
Best supportive care 187 (61–307) 119 (48–186) 4
Suicide attempt cost 1269 (801–1763)
Note. 95% Conﬁdence intervals reported between parentheses. All parameters showing conﬁdence intervals in this table were varied in the
probabilistic sensitivity analysis.
TL, Turkish lira.
Please note that the purchasing power parity between Turkey and the United States is 1.0 (2010 ﬁgure, http://stats.oecd.org).
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treatment-resistant depression adult population. A literature
search was conducted in MEDLINE covering studies published
between January 1980 and June 2010. Three PCSs for aripiprazole
[22–24], two PCSs for adjunctive quetiapine [25,26], three PCSs for
adjunctive olanzapine [27–29], one PCS for lithium [30], and one
PCS for T3 [31] were identiﬁed. Remission rates of the active
treatments and the control group were extracted. Study charac-
teristics and remission numbers are summarized in Table 3.
Subsequently, a ﬁxed effects Bayesian meta-analysis using non-
informative priors implemented in WinBUGS [32] was conducted
on the remission rates to obtain indirect odds ratios of each
treatment compared with aripiprazole [33]. The indirect odds
ratios were applied to the aripiprazole remission rate to obtain
remission rates for the other treatments (Table 2). Again, a
Bernoulli distribution was used to simulate whether a patient
would respond to a subsequent treatment line.
A patient failing three consecutive adjunctive therapies was
assumed to receive so-called best supportive care (BSC). In reality,Aripiprazole
Augmentaon
Queapine
Augmentaon
Olanzapine
Augmentaon
Lithium 
Augmentaon
T3
Augmentaon
Best Supporve
Care
Strategy 1 Strategy 2 Strategy 3
Fig. 2 – Treatment sequence strategies. T3, triiodothyronine.at this stage, medical professionals will try different therapies
including different treatment combinations. It is difﬁcult to
formally implement all these different treatment options in a
health economic model structure because of the complexity of
decisions and lack of published data to substantiate correspond-
ing efﬁcacy. Therefore, BSC grouped all these treatment alter-
natives into one for which efﬁcacy was based on the STAR*D trial,
thereby mimicking real-life practice [34]. It was anticipated that
this simpliﬁcation would not affect incremental results. STAR*D
found that 13% of the patients responded to treatment within 9.2
weeks. This was implemented in the model by drawing a
duration on BSC from an exponential distribution with a weekly
hazard rate of 0.015 (− ln(1 − 0.13)/9.2).
A patient who developed a new major depressive episode
received the same treatment as he or she had previously
responded to. No efﬁcacy data are available for patients with a
prior response to adjunctive treatment. However, it is highly
likely that this subgroup of patients will have an increased
probability of remission, reﬂected by assuming a 6-week proba-
bility of remission of 90%. This value was applied to all therapies
except for BSC, for which the duration was drawn from the same
exponential distribution as for the ﬁrst treatment episode. The
impact of the remission probability value for prior responders
was tested in a sensitivity analysis.
The assumed risk of developing a new major depressive
episode reﬂected the naturalistic data observed by Solomon
et al. [35]. They followed 318 patients suffering from MDD over
a period of 10 years and found a decrease in mean time until the
next major depressive episode with an increase in the amount of
prior episodes. Weibull curves were ﬁtted on their data (see
Fig. 3), and time until the next major depressive episode was
simulated from the appropriate distribution reﬂecting the num-
ber of prior episodes a patient had experienced. Weibull curves
were selected on the basis of a least square difference between ﬁt
and actual data. Patients in the remission and time between
episodes health states continued their antidepressant but
stopped their augmentation strategy. To date, there is no evi-
dence surrounding the impact of long-term atypical augmenta-
tion on the risk of developing a depressive episode.
Table 3 – Characteristics of studies used in indirect comparison.
Study Dur. (wk) Country Participants Methods Remission deﬁnition Placebo Active arm
N n N n
Aripiprazole Berman et al. [22] 6 US Age: 18–65 y; MDE according
to DSM-IV-TR; HAM-D-17
score ≥ 18 at end of the
screening phase; 1–3
historical ADTs of 4 6 wk
7–28-d screening phase; 8-wk
prospective treatment phase
with open-label ADT plus
single-blind adjunctive
placebo. Patients with
incomplete response
continued ADT and entered
the randomization phase.
≥ 50% decrease in
MADRS score þ
MADRS score ≤ 10
172 27 181 47
Marcus et al. [24] 6 US Same as above Same as above Same as above 184 28 185 47
Berman et al. [23] 6 US Same as above Same as above Same as above 169 32 174 64
Quetiapine McIntyre et al. [26] 8 CA Age: 18–65 y; MDE according
to DSM-IV; HAM-D-17 score
≥ 18. One historical ADT of
≥ 6 wk.
Patients treated for current
episode with single AD at
therapeutic dose for ≥ 6 wk
and meeting study criteria
for residual depressive and
comorbid anxiety symptoms
were randomized.
HAM-D-17 score ≤ 7 29 5 29 9
Bauer et al. [25] 6 AU, CA,
EU,
and
ZA
Outpatients; age: 18–65 y;
MDD according to DSM-IV-
TR; HAM-D-17 score
≥ 20; HAM-D item 1 ≥ 2.
One historical ADT of
≥ 6 wk.
Eligible patients with an
inadequate response to an
ADT during their current
episode were randomized to
6- wk double-blind
quetiapine extended release
or placebo adjunctive to
ongoing ADT.
MADRS score ≤ 10 160 50 327 134
Olanzapine Shelton et al. [27] 8 US and
CA
Age: 18–65 y; DSM-IV
unipolar, nonpsychotic
MDD; MADRS score ≥ 20 at
the beginning and the end
of the screening phase.
One historical ADT (SSRI ≥
4 wk at a therapeutic dose).
2–7-d screening/washout
phase; 7-wk lead-in phase of
nortriptyline to demonstrate
treatment failure to a TCA, 8-
wk randomized, double-
blind phase: olanzapine/
ﬂuoxetine combination,
olanzapine, ﬂuoxetine, or
nortriptyline
2 consecutive MADRS
total scores of ≤ 8
142 19 146 25
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Corya et al. [29] 12 Various Age: ≥ 18 y. DSM-IV MDD,
single or recurrent,
unipolar, without
psychotic features; CGI-S
score ≥ 4. One historical
ADT (SSRI ≥ 6 wk at a
therapeutic dose)
2–7-d screening phase; 7-wk
open-label venlafaxine lead-
in phase; patients with
o 30% improvement on
MADRS score proceeded to
5–9-d double-blind taper
phase before the
randomization phase.
2 consecutive MADRS
total scores of ≤ 8
56 10 230 69
Thase et al. [28] 8 US and
CA
Age: 18–65 y; DSM-IV MDD,
recurrent, without
psychotic features; HAM-
D-17 score ≥ 22. One
historical ADT ≥ 6 wk
3–14-d screening phase; 8-wk
open-label lead-in phase to
establish ﬂuoxetine
resistance; patients with
o 25% decrease in HAM-D-
17 score and HAM-D-17 score
≥ 18 and ≤ 15% decrease
between week 7 and 8 of
lead-in entered
MADRS score ≤ 10 at
end point
102 18 101 24
Thase et al. [28] 8 US and
CA
Same as above Same as above Same as above 101 16 97 30
Lithium Nierenberg et al.
[30]
6 US Age: 18–70 y. DSM-III-R MDD,
HAM-D-17 score ≥ 18; 1–5
historical adequate AD
courses. One prospective
ADT
1–5 adequate AD courses
failed; 6-wk prospective
open-label nortriptyline
≥ 50% decrease in
HAM-D-17
17 3 18 2
T3 Joffe et al. [31] 2 CA Mean age 37.4 y; RDC
unipolar, nonpsychotic
MD; HAM-D score ≥ 16
after 5 wk of desipramine
or imipramine
Subjects were randomly
assigned to receive 2-wk
liothyronine, lithium, or
placebo in addition to
desipramine or imipramine
≥ 50% decrease and
HAM-D score ≤ 7
16 2 17 7
AD, antidepressant; ADT, antidepressant trial/therapy; AU, Australia; CA, Canada; CGI-S, Clinical Global Impression – Severity; Dur., duration; DSM-III-R, Diagnostic and Statistical Manual of Mental
Disorders, Revised Third Edition; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revised;
EU, Europe; HAM-D-17, Hamilton rating scale for depression; MADRS, Montgomery Åsberg Depression Rating Scale; MD, major depression; MDD, major depressive disorder; MDE, major
depressive episode; N, patient population size; n, number of remitted patients; RDC, Research Diagnostic Criteria; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant, US,
United States; ZA, South Africa.
Two identical studies reported in one article.
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 1 7 1 – 1 8 0176Time of death was simulated at model entry on the basis of
general mortality statistics in Turkey taken from the World
Health Organization (http://apps.who.int/whosis/database/life_
tables/life_tables.cfm, accessed April 2010). The risk of suicide
during major depressive episodes was based on information from
Bernal et al. [36] who found a 3.91-fold (95% conﬁdence interval
2.74–5.6) higher suicide risk for patients with MDD relative to the
general population. According to Devrimci-Ozguven and Sayil
[37], suicide risk in the general Turkish population was 112.11 per
100,000 inhabitants in 2001. This gives an estimated suicide
attempt probability (rate) of 0.4% (0.044) per year for patients
with MDD in Turkey. A constant hazard rate was assumed for
determining the probability of attempting suicide, based on the
patient’s actual depressive episode duration. The model imputed
an 8.3% probability that an attempted suicide resulted in death,
which was based on Bilici et al. [38] who found 2.6 completed
suicides out of 31.5 attempts per 100,000 person-years.
Utility Weights
No speciﬁc utility values for Turkish patients with MDD were
available at the time of this research. A Swedish study by Sobocki
et al. [10,16], however, reported utility values for patients with
moderate depression (Clinical Global Impression – Severity score
of 4) and remission, based on a naturalistic longitudinal obser-
vational study of 447 patients in primary care. Utilities were
derived from patients’ EuroQol ﬁve-dimensional questionnaire
health status questionnaires, applying UK national tariff in the
absence of speciﬁc social tariffs for Sweden at the time of their
study [10]. Utility values were applied to the depressive episode
and remission health states in the model. It was assumed that
the quality of life of patients in the between episodes health state
resembled the quality of life in the general population [39] (see
also Table 2).
Cost Data
Drug prices were extracted from the Turkish Ministry of Health,
Directorate of Pharmaceuticals Ofﬁcial Web Page on February 2,
2010 [40], and adjusted for mandatory discounts to obtain0%
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Fig. 3 – Time until next episode per number of prior episodes. Da
survival curve ﬁts.reimbursed prices. It was assumed that all patients would incur
the same background antidepressant cost during the entire
model horizon. Background antidepressant costs were calculated
as a weighted average cost of the antidepressants used at
randomization in the clinical trials of aripiprazole augmentation
[22–24]. Augmentation treatment costs were incurred during
depressive episodes. Health care resource use during a depressive
episode is generally higher than during remission periods.
Turkish-speciﬁc data about resource use is available only for
patients with MDD in general without stratiﬁcation between both
states [41]. A Swedish study, however, has shown that patients in
a depressive episode and a remission episode have 1.24 and
0.8 times the medical resource consumption of an average
patient with MDD, respectively [16]. The number of psychiatrist
visits and the average number of hospitalization days were
obtained from Karamustafalioglu et al. [41] and multiplied with
corresponding Turkish unit costs [42] to obtain health care
resource costs for an average patient with MDD. The ratios from
Sobocki et al. [16] were multiplied with this number to obtain
depressive and remission cost estimates for Turkey. Costs during
the between episodes state were assumed to reﬂect only the
antidepressant use. The cost of suicide attempts was based on
Karamustafalioglu et al. [41], including only the costs of care
received. Total weekly costs per health state and adjunctive
treatment are outlined in Table 2. Please note that remission
cost and between episode cost are identical for all treatments
because there is no differentiation in treatment costs opposed to
the depressive episode phase. Costs and quality-adjusted life-
years (QALYs) were discounted with 3.5% per annum.
Probabilistic Sensitivity Analysis
As with all health-economic models, the input parameters are
subject to uncertainty. To describe the inﬂuence of the uncer-
tainty in model parameters on the incremental model outcomes,
a probabilistic sensitivity analysis (PSA) was conducted. The joint
uncertainty surrounding incremental costs and effects following
from the uncertainty around all model input parameters was
addressed by generating 1000 random sets of input parameters,
using probability distributions for each parameter that reﬂect its2.5 3 3.5 4 4.5 5
us depressive episode (years)
1 prior episode
2 prior episodes
3 prior episodes
4 prior episodes
5 prior episodes
ta points are from Solomon et al. [35]. Lines represent Weibul
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conﬁdence intervals for each parameter are presented in Table 2.
A major source of the uncertainty in incremental model outcomes
is the uncertainty surrounding the difference in remission rates
between adjunctive aripiprazole and adjunctive quetiapine and
olanzapine as represented by their respective odds ratios. The
uncertainty surrounding these inputs was based on the joint
posterior distribution obtained from the indirect comparison.
The corresponding uncertainty surrounding the remission rates
of adjunctive quetapine and olanzapine is presented in Table 2.
Utility values were varied by using beta –distributions, and the
costs inputs were varied by using gamma distributions. A scatter
plot was generated, showing the 1000 combinations of incremen-
tal costs and effects generated from the PSA. Corresponding cost-
effectiveness acceptability curves were drawn, showing the prob-
ability that adjunctive aripiprazole augmentation is cost-effective
compared with adjunctive quetiapine and olanzapine at various
levels of willingness to pay (WTP) per QALY gained.Results
Base Case
Results for the comparison of adjunctive aripiprazole with adjunc-
tive quetiapine and adjunctive olanzapine are presented in Table 4.
Costs are presented in Turkish lira (TL), which has a purchasing
power parity of 1.0 compared with the US dollar (2010 ﬁgure, http://
stats.oecd.org). The average life expectancy of a patient in themodel
is 31.6 years, with an average starting age of 45 years, implying that
patients, on average, live to be 76 years old. The minor difference inTable 4 – Health economic model results.
Outcome Aripiprazole
augmentation
Quetiapine
augmentation
Ola
aug
Life expectancy (y) 31.62 31.61
Time spent in
depressive
episodes (y)
9.44 9.64
Time spent in
remission (y)
8.88 8.81
Time spent between
episodes (y)
13.31 13.17
Percentage of
patients
attempting suicide
4.30 4.30
Percentage of
patients
completing suicide
0.30 0.33
QALYs (discounted) 13.62 13.56
Total costs ($/TL) 84,800 85,393 85,2
Antidepressant 3,840 3,839 3,8
Augmentation 580 222 3
Psychiatrist visits 20,265 20,504 20,4
Hospitalization 60,086 60,798 60,6
Suicide 29 29
QALY, quality-adjusted life-years; TL, Turkish lira.
Please note that the purchasing power parity between Turkey and the U
table may not add up because of rounding errors.life expectancy between the different treatment sequences is
explained by a difference in completed suicides. Aripiprazole
augmentation has fewer attempted and thereby fewer committed
suicides compared with adjunctive quetiapine and olanzapine. This
difference is explained by the lesser time spent in major depressive
episodes with aripiprazole, during which patients are exposed to the
risk of suicide (11 and 7 weeks less compared with quetiapine and
olanzapine augmentation). Because of a higher remission rate with
adjunctive aripiprazole, on average, patients treated with adjunctive
aripiprazole spend less time in the depression state than do those
treated with adjunctive quetiapine and olanzapine. Because the
depressive episode is associated with diminished quality of life,
patients starting with aripiprazole augmentation gain 0.054 and
0.039 QALYs on average than do those starting with quetiapine
augmentation and olanzapine augmentation, respectively.
A major cost driver in the model is hospitalization costs, which
comprise approximately 71% of total costs. Because patients in the
depressive episode are more likely to be hospitalized and patients
in the aripiprazole augmentation arm spend less time in that
episode, hospitalization costs are saved compared with quetiapine
augmentation (712 TL) and olanzapine augmentation (554 TL). A
similar pattern is observed for psychiatrist visit costs (savings of
240 TL and 174 TL, respectively). Augmentation costs for the
aripiprazole augmentation arm are higher than for quetiapine
and olanzapine augmentation arms due to the higher drug acquis-
ition costs for aripiprazole. Because of the savings on hospital-
ization and psychiatrist visit costs, however, aripiprazole
augmentation saves, on average, 593 TL and 485 TL per patient
than do quetiapine and olanzapine augmentation, respectively.
Dominance of aripiprazole augmentation was independent of
the remission probability value for prior responders.nzapine-
mentation
Difference
aripiprazole with
quetiapine
Difference
aripiprazole with
olanzapine
31.62 0.012 0.010
9.58 −0.21 −0.14
8.83 0.08 0.06
13.22 0.14 0.09
4.33 −0.01 −0.04
0.34 −0.03 −0.04
13.58 0.054 (−0.038 to 0.213) 0.039 (−0.048 to 0.171)
85 −593 (−3780 to 619) −485 (−3132 to 757)
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04 −712 −554
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The scatter plot illustrated in Figure 4 represents the joint
uncertainty surrounding incremental QALYs and incremental
costs for both comparisons, based on 1000 Monte Carlo
simulations. This is a result of the combined uncertainty sur-
rounding all model parameters, including efﬁcacy, quality of
life, and cost inputs. Scatter points in the lower right quad-
rant represent instances in which aripiprazole augmentation
improves quality of life and saves costs. This occurs in 85% and
86% of the cases for the comparison with quetiapine and
olanzapine, respectively. The top left quadrant represents instan-
ces in which aripiprazole augmentation decreases quality
of life and is more expensive. This occurs in 13% of the cases0%
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Fig. 5 – Cost-effectiveness acceptability curves. QALfor both comparisons. The uncertainty surrounding results is
mainly driven by the uncertainty around the remission
probabilities for aripiprazole, quetiapine, and olanzapine
augmentation.
Figure 5 presents the cost-effectiveness acceptability curves
for the three treatment strategies showing the probability that
each of them is cost-effective at various WTP thresholds. If one is
interested only in health gains at no additional costs, aripiprazole
augmentation has a probability of being cost-effective of 74%,
whereas quetiapine and olanzapine each have a probability of
13% to be cost-effective. The acceptability lines remain relatively
stable at various WTP levels. This is because only 2% of the
scatter points for both comparisons are in the northeast and
southwest quadrants, where an actual trade-off is made between$ \ TL 60,000 $ \ TL 80,000 $ \ TL 100,000
Pay per QALY gained
Aripiprazole
Queapine
Olanzapine
Y, quality-adjusted life-year; TL, Turkish lira.
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values ranging from 0 to 100,000 TL per QALY gained, the
probability that aripiprazole is cost-effective among all three
strategies varies between 74% and 75%.Discussion
The objective of this research was to assess the cost-effectiveness
of adjunctive aripiprazole treatment compared with adjunctive
quetiapine and olanzapine treatment in patients with MDD who
had an insufﬁcient response to antidepressant treatment in
Turkey.
A patient-level simulation model was developed simulating
the chronic and deteriorating course of the disease, as well as the
sequence of treatment steps.
The model results showed that adjunctive aripiprazole is
dominant compared with quetiapine and olanzapine. Patients
starting with adjunctive aripiprazole spend 11 weeks and 7 weeks
less in major depressive episodes than do patients starting with
quetiapine and olanzapine, respectively. This translates to 0.054
and 0.039 QALY gains, respectively. Despite the higher drug
acquisition cost, on average, the total cost for a patient starting
with adjunctive aripiprazole is 593 TL and 485 TL less than those
for a patient starting with adjunctive quetiapine and olanzapine,
respectively. These savings are mainly explained by less hospital-
ization costs and fewer psychiatrist visits. The increased remis-
sion rate of adjunctive aripiprazole compared with quetiapine
and olanzapine underlies the health gains and cost savings. The
difference in remission rates between adjunctive aripiprazole,
quetiapine, and olanzapine were obtained from an indirect
comparison, combining the available evidence reported in the
published literature by using 10 identiﬁed PCSs [22–31]. The
inﬂuence of the uncertainty in the estimated differences in
remission rates between the three adjunctive atypical antipsy-
chotic treatments resulting from this indirect comparison was
incorporated in a PSA. In addition, the uncertainty surrounding
the other model inputs was incorporated in the PSA. The
probability that adjunctive aripiprazole would be cost-effective
among the three strategies ranged between 74% and 75% for WTP
values between 0 TL and 100,000 TL per QALY gained.
To ensure that the model resembled Turkish clinical practice,
resource use, unit cost, and mortality data were based on Turkish
sources. To the best of our knowledge, no lifetime cost-
effectiveness models in this indication have been published.
Previously published cost-effectiveness models in MDD are lim-
ited. Only two lifetime horizon models have been published so
far, both by Revicki et al. in 1995 and 1997 [43,44]. Economic
guidelines by the National Institute for Health and Clinical
Excellence [45] and Drummond and Jefferson [46] recommend a
lifetime model horizon in the case of chronic illnesses such as
depression. Also, the deteriorating course of depression should
ideally be captured in the model. This is, however, possible only
when the model is able to take the history of a patient into
account. Until now, the only published model in which patients
could experience multiple recurrences was a Markov model
published by Sobocki et al. in 2006 [47].
A recent cost-effectiveness analysis in the United States also
compared adjunctive aripiprazole, quetiapine, and olanzapine for
acute treatment of MDD [21]. It was concluded that the cost per
additional responder was lower for aripiprazole than for quetia-
pine or olanzapine/ﬂuoxetine [21]. In the present analysis, aripi-
prazole is not only more effective but also cost saving. This
difference is likely due to the short horizon length of the US
analysis (6 weeks only) that cannot capture future cost savings.Limitations
Because of a lack of Turkish evidence, Swedish-speciﬁc utility
values were used. Different utility values, however, would impact
only the magnitude of QALYs gained. As such, the base-case and
PSA conclusions are independent of country-speciﬁc utilities. Clin-
ical trial data were largely based on US populations; however, it is
not expected that these would be different in a Turkish population.
The only data available for adjunctive aripiprazole in MDD
consider the treatment of acute depressive episodes for a duration
of 6 weeks. This is also the case for the comparators. The impact on
relapse prevention of adjunctive aripiprazole is yet to be inves-
tigated. As such, the differences in outcomes between the three
adjunctive atypical antipsychotic treatments are solely based on the
differences observed during the acute depressive episode treat-
ment. When additional data about relapse prevention become
available, however, the model can be adjusted to incorporate this.
The relative efﬁcacies of the three treatments are major drivers of
uncertainty in the incremental outcomes. Preferably, these should
be based on direct comparable data; however, such trials have not
been conducted so far, which is why an indirect comparison of PCSs
was used for this research. If direct comparable evidence would
become available in the future, this can be imputed in the model.
Adverse events are not included in the model. This is because
augmentation treatment is given only for a short period of time
and most important side effects for these drugs will develop
when taking the drug for a longer duration. Aripiprazole aug-
mentation treatment is associated with akathisia. This side effect
was not implemented in the model. This is because akathasia
will be present only in the 6 weeks of treatment and will
therefore have a minor inﬂuence on the total model outcomes.
However, side effects commonly associated with quetiapine and
olanzapine (such as extrapyrimidal syndrome, weight gain, and
diabetes) are also not incorporated. Because of the relatively
short amount of time in which the drugs are given in the model
and the already high disability of the disease itself, it is expected
that incorporating side effects would have only a minor inﬂuence
on model outcomes and omitting them is expected to be a
conservative approach for aripiprazole.
Costs associated with monitoring tests during atypical anti-
psychotic use were not incorporated. Because monitoring would
be required for all three atypical augmentation regimes com-
pared, this would not affect incremental costs.
When implementing long-term data on the effects of aripi-
prazole augmentation in the model, side effects should be taken
into account. In the long run, the chronic use of antipsychotic
medication is a risk factor for developing diabetes mellitus type 2
and extensive weight gain. There is evidence, however, substan-
tiating that aripiprazole is an exception and will have less impact
on these side effects than, for example, quetiapine or olanzapine.
Indirect costs associated with work productivity losses, which
are not uncommon in patients with MDD, are not considered by
the Turkish payer, which is why these were excluded from the
analysis. Including indirect costs, however, would likely result in
further cost savings for aripipazole augmentation. Less time is
spent in depressive episodes with this treatment, during which
patients have a higher chance of incurring work productivity
losses than during phases of remission.Conclusions
The cost-effectiveness model described here showed that aripi-
prazole augmentation dominates quetiapine augmentation and
olanzapine augmentation. Taking into account the uncertainty in
all model input parameters, the probability that adjunctive
aripiprazole would be cost-effective among the three strategies
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 1 7 1 – 1 8 0180ranged between 74% and 75% for WTP values between 0 TL and
100,000 TL per QALY gained. Although atypical antipsychotics
have the same reimbursement status for augmentation treat-
ment of MDD in Turkey, these economic ﬁndings may help
inform clinicians in their choice of antipsychotic augmentation.
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